Overview
A Phase 1,Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Recruiting
Trial end date:
2023-07-31
2023-07-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
Evaluate the safety and tolerability of BPI-421286 in adult subjects with advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with advanced solid tumors.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Betta Pharmaceuticals Co., Ltd.
Criteria
Inclusion Criteria:- Pathologically documented, locally-advanced or metastatic malignancy
- Standard treatment is not available or patient declines
- Adequate organ function
Exclusion Criteria:
- Active brain metastases from non-brain tumors.
- Gastrointestinal (GI) tract disease causing the inability to take oral medication.
- Other protocol specified criteria